Rapid Dose Therapeutics Corp.

Equities

DOSE

CA75339A1012

Medical Equipment, Supplies & Distribution

Market Closed - Canadian Securities Exchange 10:38:15 2024-04-26 am EDT 5-day change 1st Jan Change
0.255 CAD 0.00% Intraday chart for Rapid Dose Therapeutics Corp. +24.39% +54.55%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in funding CI
Rapid Dose Therapeutics Corp. Appoints Angela O'Leary to the Board of Directors CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023 CI
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 7 million in funding CI
Rapid Dose Therapeutics Corp. announced that it has received CAD 3.134445 million in funding CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023 CI
Rapid Dose Therapeutics Corp. Announces the Resignation of Andrew Duckman from the Company's Board of Directors CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the First Quarter Ended May 28, 2023 CI
Rapid Dose Therapeutics Narrows Fiscal Q4 Loss, Revenue Grows MT
Rapid Dose Therapeutics Corp. Auditor Raises 'Going Concern' Doubt CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the Full Year Ended February 28, 2023 CI
Rapid Dose Increased Proposed Private Placement Financing of Up to $5 Million; Gained 30% on Tuesday MT
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 3 million in funding CI
Rapid Dose Therapeutics Corp. Launches QuickStrip™ Dental Products in the Canadian Market CI
Rapid Dose Therapeutics Corp. Announces Changes to Its Board of Directors CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2022 CI
Rapid Dose Therapeutics Corp. Auditor Raises 'Going Concern' Doubt CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the First Quarter Ended May 31, 2022 CI
Rapid Dose Therapeutics Brief: Says Co and its Auditors Continuing to work "diligently" to complete Audit of Annual financial statements for the fiscal year ended February 28, 2022 MT
Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order MT
Rapid Dose Therapeutics Corp. Enters Supplier and Purchase Agreement with A Leading Gas and Convenience Store Retailer for Nutraceutical and Vitamin Products CI
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 5 million in funding CI
Rapid Dose Therapeutics Corp. announced a financing transaction CI
Rapid Dose Therapeutics Corp. Provides Shareholder Update Regarding Vaccine Collaboration Agreement with Oakland Health Limited in the United Kingdom CI
Rapid Dose Therapeutics Corp. and Skycare Compounding Labs to Provide Patients with Novel Oral Delivery Option for Pharmaceutical Products CI
Chart Rapid Dose Therapeutics Corp.
More charts
Rapid Dose Therapeutics Corp. is a Canadian biotechnology company. The Company provides disruptive drug delivery technologies designed to improve patient outcomes. The Company’s flagship product, QuickStrip, is a thin, orally dissolvable film that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals, and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. It offers over-the-counter and pharmaceutical drug delivery solutions. Its QuickStrip Energy delivers energizing caffeine. Its QuickStrip B12 delivers vitamin B12 to the system, assisting with metabolism and physical energy. Its QuickStrip Sleep delivers melatonin to the system, inducing natural and healthy sleep. QuickStrip Lidocaine is its dental product. The Company also provides production and consultation to the nutraceutical, cannabis healthcare and pharmaceutical manufacturing industries.
More about the company
  1. Stock Market
  2. Equities
  3. DOSE Stock
  4. News Rapid Dose Therapeutics Corp.
  5. Rapid Dose Therapeutics Narrows Fiscal Q4 Loss, Revenue Grows